- Home
- JHX vs EXEL Comparison
JHX vs EXEL Comparison
Compare JHX & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JHX | EXEL |
|---|---|---|
| Founded | 1888 | 1994 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 11.1B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | JHX | EXEL |
|---|---|---|
| Price | $19.94 | $44.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 24 |
| Target Price | $28.60 | ★ $44.73 |
| AVG Volume (30 Days) | ★ 6.6M | 2.5M |
| Earning Date | 11-17-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.55 |
| EPS | 0.40 | ★ 2.38 |
| Revenue | ★ $4,116,899,999.00 | $2,288,218,000.00 |
| Revenue This Year | $24.54 | $9.14 |
| Revenue Next Year | $15.32 | $12.51 |
| P/E Ratio | $59.44 | ★ $18.67 |
| Revenue Growth | 4.60 | ★ 9.93 |
| 52 Week Low | $16.46 | $31.90 |
| 52 Week High | $29.83 | $49.62 |
Technical Indicators
Market Signals| Indicator | JHX | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 58.78 | 63.52 |
| Support Level | $19.14 | $43.00 |
| Resistance Level | $19.90 | $44.79 |
| Average True Range (ATR) | 0.57 | 1.03 |
| MACD | 0.31 | 0.06 |
| Stochastic Oscillator | 97.74 | 83.48 |
Price Performance
Historical ComparisonAbout JHX James Hardie Industries plc (Ireland)
James Hardie is a manufacturer of fiber cement-based building products, selling primarily to the residential construction industry. North America is the primary geography, generating about 80% of group earnings. Here, it is the largest manufacturer of fiber cement, which is mainly used for exterior siding on houses. Following the Azek acquisition in 2025, it also produces wooden composite decking materials, siding trims, and accessories for outdoor areas including stair and deck railing. Businesses in Australia, New Zealand, and Europe, make up the rest of earnings.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.